±Ù½Ã ±³Á¤ ·»Áî ½ÃÀå : Á¦Ç° À¯Çüº°, ·»Áî À¯Çüº°, ¿¬·ÉÃþº°, À¯Åë ä³Îº°, Áö¿ªº°
Myopia Control Lenses Market, By Product Type, By Lens Type, By Age Group, By Distribution Channel, By Geography
»óǰÄÚµå : 1741284
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,183,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,619,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,742,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

±Ù½Ã ±³Á¤ ·»Áî ½ÃÀåÀº 2025³â¿¡´Â 19¾ï 1,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, 2032³â¿¡´Â 46¾ï 9,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â±îÁöÀÇ CAGRÀº 13.7%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ ¿¬µµ 2024³â ½ÃÀå ±Ô¸ð(2025³â) 19¾ï 1,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø±â°£ CAGR(2025-2032³â) 13.70% °¡Ä¡ ¿¹Ãø(2032³â) 46¾ï 9,000¸¸ ´Þ·¯

±Ù½Ã´Â ½É°¢ÇÑ ¸Á¸· Áúȯ°ú ½Ã·Â ÀúÇÏ µî »îÀÇ ÈĹݿ¡ Çö½ÇÀûÀÎ ´« ¹®Á¦·Î À̾îÁú ¼ö Àֱ⠶§¹®¿¡ ¾î¸°ÀÌ¿Í Ã»¼Ò³â ¼ºÀÎ »çÀÌ¿¡¼­ Å« ¹®Á¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 3¿ù¿¡ ¿µ±¹ ¾È°úÇÐȸÁö¿¡ ¹ßÇ¥µÈ ¿¬±¸¿¡ µû¸£¸é 7-9¼¼(33.1%)¿Í 10-12¼¼(29.4%) ¾î¸°ÀÌÀÇ ±Ù½Ã ÁøÇà·üÀÌ ´Ù¸¥ ±×·ì(ÃÖ´ë 22.1%)¿¡ ºñÇØ ³ô´Ù´Â °á·ÐÀ» ³»·È½À´Ï´Ù. ±Ù½Ã°¡ -4.00 ´ÜÀ§ ÀÌ»óÀÌ¶óµµ 10´ë°¡ µÉ ¶§±îÁö ±Ù½Ã°¡ ´õ ½É°¢ÇÑ ÇüÅ·ΠÁøÇàÇÒ À§ÇèÀÌ ³ô¾ÆÁö±â ¶§¹®¿¡ ±Ù½Ã°¡ ¾ÇÈ­µÇÁö ¾Êµµ·Ï Á¶±â¿¡ Ä¡·áÇÏ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù.

±Ù½Ã¸¦ ±³Á¤Çϱâ À§ÇØ ´Ù¾çÇÑ Ä¡·á¹ýÀÌ ÀÖ½À´Ï´Ù¸¸, ±× Áß¿¡¼­µµ ÃÖ½ÅÀÇ ±Ù½Ã ±³Á¤¹ýÀº ±Ù½Ã ±³Á¤°ú ±Ù½Ã ÁøÇà ¿¹¹æÀ» µ¿½Ã¿¡ ½Ç½ÃÇϴ Ư¼öÇÑ ÄÜÅÃÆ®·»Á »ç¿ëÇÏ´Â ¹æ¹ýÀÔ´Ï´Ù. ·»ÁîÀÇ Áß¾Ó ºÎºÐ¿¡ ±Ù½Ã ±³Á¤ ±â´ÉÀ» °®°Ô ÇØ, ±× ÁÖÀ§¸¦ ¸µÀ¸·Î ±³´ë·Î µÑ·¯½Î´Â ÀÌÁß ÃÊÁ¡ ¹æ½ÄÀ» ä¿ëÇϰí ÀÖ½À´Ï´Ù. °¢ ¸µÀº ±Ù½ÃÀÇ ¾ïÁ¦ ¶Ç´Â ±Ù½ÃÀÇ º¸Á¶¸¦ ½Ç½ÃÇϵµ·Ï ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

±Ù½Ã ±³Á¤ ·»Áî ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ÁÖ¿ä ¿øµ¿·ÂÀº ÁÖ·Î ¾î¸°ÀÌ¿Í ¼ºÀå±âÀÇ ¼ºÀÎ »çÀÌ¿¡¼­ ±Ù½ÃÀÇ ¹ß»ý·üÀÌ °è¼Ó Áõ°¡Çϰí ÀÖ´Â °ÍÀÔ´Ï´Ù. ±Ã±ØÀûÀ¸·Î´Â ÀÌ ¹®Á¦¸¦ ÇØ°áÇÏ°í ´« °Ç°­¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡¿Í ¿ì·Á·Î ÀÎÇÑ À§ÇèÀ» ÁÙÀ̱â À§ÇÑ ¿¹¹æ Á¶Ä¡·Î ±Ù½Ã ±³Á¤ ·»Á ä¿ëÇØ¾ß ÇÕ´Ï´Ù. 2023³â 8¿ù, Çö´ë °Ë¾ÈÇп¡¼­ ¹ßÇ¥ÇÑ ±â»ç¿¡ µû¸£¸é ±Ù½ÃÀÇ Àü ¼¼°è ¹ßº´·üÀº 2010³â 27%¿¡¼­ 2020³â 33%·Î Áõ°¡Çß½À´Ï´Ù.

¶ÇÇÑ ·»Áî ±â¼úÀÇ ²÷ÀÓ¾ø´Â Áøº¸·Î ±Ù½Ã ±³Á¤ ·»Áî ½ÃÀåµµ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¼ºÀ» Áõ¸íÇÏ´Â °­·ÂÇÑ Áõ°Å´Â ¸¹Àº ¿¬±¸¿¡ ÀÇÇØ Á¦½ÃµÇ¾î ¾ÆÀÌ Äɾî Àü¹®°¡¿¡ ÀÇÇÑ ¼ö¿ë°ú ÁöÁö¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 4¿ù 27ÀÏ ¹Ì±¹ ´º¿Ã¸®¾ð½º¿¡¼­ ¿­¸° 2023 ARVO ¿¬·Ê ȸÀÇ¿¡¼­ °íǰÁú ½Ã·Â °ü¸® Á¦Ç° Á¦Á¶¾÷üÀÎ ¿¡½Ç·Î·è¼ÒƼī´Â ±Ù½Ã Á¶Àý Çõ½Å ·»ÁîÀÎ ¿¡½Ç·Î ½ºÅÚ·¹½ºÆ® ·»ÁîÀÇ 4³â°£ ÀÓ»ó ¿¬±¸ °á°ú¸¦ ÃÖÃÊ·Î °ø°³Çß½À´Ï´Ù.

±×·¯³ª, ±Ù½Ã ±³Á¤¿¡ ´ëÇÑ ÀνÄÀÌ Àα¸ »çÀÌ¿¡¼­ Á¦ÇÑµÇ°í ±Ù½Ã ±³Á¤ ·»ÁîÀÇ ºñ¿ëÀÌ ³ô´Ù(¿¹¸¦ µé¾î, ¿À¸£¼ÒÄɶóÅç·ÎÁö ·»Áî)´Â Á¶±â ±â°£ µ¿¾È ¼¼°èÀÇ ±Ù½Ã ±³Á¤ ·»Áî ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ±Ù½Ã ±³Á¤ ·»Áî ½ÃÀå - Äڷγª ¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ±Ù½Ã ±³Á¤ ·»Áî ½ÃÀå, Á¦Ç° À¯Çüº°(2020-2032³â)

Á¦6Àå ¼¼°èÀÇ ±Ù½Ã ±³Á¤ ·»Áî ½ÃÀå, ·»Áî À¯Çüº°(2020-2032³â)

Á¦7Àå ¼¼°èÀÇ ±Ù½Ã ±³Á¤ ·»Áî ½ÃÀå, ¿¬·ÉÃþº°(2020-2032³â)

Á¦8Àå ¼¼°èÀÇ ±Ù½Ã ±³Á¤ ·»Áî ½ÃÀå, À¯Åë ä³Îº°(2020-2032³â)

Á¦9Àå ¼¼°èÀÇ ±Ù½Ã ±³Á¤ ·»Áî ½ÃÀå, Áö¿ªº°(2020-2032³â)

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ¼½¼Ç

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Myopia Control Lenses Market is estimated to be valued at USD 1.91 Bn in 2025 and is expected to reach USD 4.69 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.7% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 1.91 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 13.70% 2032 Value Projection: USD 4.69 Bn

Nearsightedness is a major problem among children and young adults as it can lead to real eye problems later in life, including serious retinal diseases and vision loss. Studies have shown that myopia can progress to a more dangerous level by the time a child is a teen or young adult. For instance, in March 2021, a study published by British Journal of Ophthalmology concluded that myopia progression among children aged 7-9 years (33.1%) and 10-12 years (29.4%) was higher as compared to other groups (at most 22.1%). Even amounts of nearsightedness -4.00 units or more, increases the risk of myopia progressing into a more serious form by the time the child reaches teen age, so it is important to treat myopia early to prevent it from getting worse.

Various treatments are available to control myopia, among which the latest myopia control method involves a special contact lens that is designed to simultaneously correct myopia and prevent myopia progression. It works by using a dual-focus approach whereby the central area of the lens contains myopia correction and alternating rings surround this region, with each ring being configured to provide either myopia control or near addition.

Market Dynamics

The major driving factor that is responsible for boosting the myopia control lenses market growth is the ever-increasing incidence of myopia, mostly among the children and the growing adults. With its rise, there is increase in demand for solutions to control its spread which ultimately requires the adoption of myopia control lenses as a preventative measure to address the problem and lower the possible hazards which is motivated by the increased awareness of and concern for eye health. In August 2023, according to an article published by Modern Optometry, the myopia's global incidence is increasing, rising from 27% in 2010 to 33% in 2020. It is anticipated that 52% of the global population will be myopic by 2050, with 10% of those people having extreme myopia.

Also, the market for myopia control lenses has grown significantly as a result of the continuous progress in lens technology. Manufacturers are creating specialty lenses with cutting-edge materials and designs to effectively stop the growth of myopia. The growing number of clinical studies and scientific evidence proves the effectiveness of myopia control lenses which had a significant impact on market expansion. Strong proof for the efficiency of myopia control lenses has been presented by numerous studies, which has enhanced their acceptance and endorsement by eyecare specialists. For instance, on April 27, 2023, EssilorLuxottica, a manufacturer of high-quality vision care products, revealed the four-year clinical study findings of its myopia control innovation Essilor Stellest lens for the first time at the 2023 ARVO annual meeting in New Orleans,U.S.. The findings reveal that Essilor Stellest lenses continue to be effective in decreasing myopia progression and axial eye elongation in children in their fourth year.

However, the limited cognizance about controlling myopia amongst the population and the high cost of myopia lenses being high (for ex: orthokeratology lenses), is expected to hinder the market growth of the global myopia control lenses market over the fasted period.

Key features of the study:

Global Myopia Control Lenses Market Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Myopia Control Lenses Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Myopia Control Lenses Market, By Product Type, 2020-2032, (US$ Bn)

6. Global Myopia Control Lenses Market, By Lens Type, 2020-2032, (US$ Bn)

7. Global Myopia Control Lenses Market, By Age Group, 2020-2032, (US$ Bn)

8. Global Myopia Control Lenses Market, By Distribution Channel, 2020-2032, (US$ Bn)

9. Global Myopia Control Lenses Market, By Region, 2020-2032, (US$ Bn)

10. Competitive Landscape

11. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â